Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy

Table 1 Clinical characteristics of 154 patients with OSCC after definitive CCRT

Factors	Training cohort n (%)	Validation cohort n (%)	p value
Age, years			0.087^b
Median (range)	61 (37–76)	58 (40–76)
Sex			0.841^c
Male	77 (77.8%)	42 (76.4%)
Female	22 (22.2%)	13 (23.6%)
Tumour location			0.325^c
Cervical	16 (16.2%)	13 (23.6%)
Upper	54 (54.5%)	31 (56.4%)
Middle	29 (29.3%)	11 (20.0%)
T stage^a			0.469^c
T2	11 (11.1%)	10 (18.2%)
T3	46 (46.5%)	24 (43.6%)
T4	42 (42.4%)	21 (38.2%)
N stage^a			0.655^c
N0	36 (36.4%)	22 (40.0%)
N1	63 (63.6%)	33 (60.0%)
M stage^a			0.668^c
M0	87 (87.9%)	47 (85.5%)
M1	12 (12.1%)	8 (14.5%)
Clinical stage^a			0.909^c
II stage	29 (29.3%)	16 (29.1%)
III stage	58 (58.6%)	31 (56.4%)
IV stage	12 (12.1%)	8 (14.5%)
Chemotherapy regimen			0.559^c
RT with PF	91 (91.9%)	49 (89.1%)
RT with other regimens	8 (8.1%)	6 (10.9%)
Dose regimen			0.102^c
2.2 Gy × 30 F	55 (55.6%)	23 (41.8%)
2.0 Gy × 32 F	44 (44.4%)	32 (58.2%)

OSCC, oesophageal squamous cell carcinoma; CCRT, concurrent chemoradiotherapy; AJCC, American Joint Committee on Cancer staging system (version 6.0th); RT, radiotherapy; PF, cisplatin and 5-fluorouracil
^aAmerican Joint Committee on Cancer (AJCC) staging system (version 6.0th)
^bp value was analysed using the independent samples t-test
^cp value was analysed using the chi-squared test

ISSN: 1748-717X